share_log

Autolus Therapeutics Raises $100M Via Equity

Autolus Therapeutics Raises $100M Via Equity

Autolus治療公司通過股權籌集1億美元
Benzinga Real-time News ·  2021/02/10 19:59
  • Autolus Therapeutics PLC (NASDAQ: AUTL) prices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares (ADS) representing 14.3 million ordinary shares at $7 per ADS, for total gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 2.1 million ADSs.
  • The offering is expected to close on February 12.
  • J.P. Morgan and Wells Fargo Securities are acting as joint book-runners for the offering.
  • Autolus did not mention the use for the proceeds raised. Still, last month, it prioritized the development of AUTO1 and thus planned to cut headcount by approximately 20% resulting in annualized savings of $15 million. AUTO1 is under development for adult acute lymphoblastic leukemia, with full data from the AUTO1-AL1 study expected in 2022.
  • Autolus plans to seek a partner for the AUTO3 program, its CAR T product candidate for relapsed/refractory diffuse large B cell lymphoma, ahead of progressing into the next phase of development.
  • Price Action: AUTL slid 2% at $7.35 during the premarket trading on the last check Wednesday.
  • Autolus Treateutics PLC(納斯達克：AUTL) 為承銷的公開發行定價在美國，1,430萬股美國存托股份(ADS)相當於1,430萬股普通股，每股ADS 7美元，總收益約為1億美元。承銷商有權再購買至多210萬隻美國存託憑證。
  • 此次發行預計將於2月12日結束。
  • 摩根大通(J.P.Morgan)和富國銀行證券(Wells Fargo Securities)將擔任此次發行的聯合簿記管理人。
  • Autolus沒有提到募集資金的用途。儘管如此，上個月，它還是優先考慮了AUTO1的開發，因此計劃裁員大約20%，年化節省1500萬美元。AUTO1正在開發用於成人急性淋巴細胞白血病的AUTO1，預計2022年將有AUTO1-AL1研究的完整數據。
  • Autolus計劃在進入下一階段開發之前，為其治療復發/難治性瀰漫性大B細胞淋巴瘤的CAR T產品候選AUTO3計劃尋找合作伙伴。
  • 價格行動：在週三最後一次檢查的盤前交易中，AUTL下跌2%，至7.35美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論